This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

Described is an optimized process for parvovirus production including an essentially serum-free medium which is suitable to increase parvovirus production compared to a standard medium, preferably for H-1PV production.

The invention is directed to compositions and methods for collecting, transporting, and storing, preferably without refrigeration, biological materials, which may comprise samples of biological, clinical, forensic, and/or environmental origin. Compositions preserve the fidelity and/or viability of the collected organisms and/or macromolecules in the sample and permit long-term storage. Compositions are compatible with manipulation of the sample, including propagation and culture of the microorganisms, or isolation, purification, detection, and characterization of macromolecules. Compositions containing microorganisms or macromolecules can be further processed, for example, by nucleic acid testing with greater fidelity and detection as compared to conventional microbial transport media. In particular, the compositions disclosed allow for the safe collection, transport and storage of biological samples for extended periods at ambient temperature, while maintaining the integrity of the macromolecules of the sample for subsequent extraction, identification, and quantitation.

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.

Peptide-based molecules for modulating expression or accessibility to the coxsackievirus and adenovirus receptor (CAR) are disclosed. Cell-permeable peptide-based molecules having a PDZ-decoy domain or PDZ-binding domain are used to modulate the expression or accessibility of CAR molecules, thereby affecting the ability of viral molecules, or molecules containing viral sequences or proteins able to bind CAR, to enter host cells.

This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.

Described is an optimized process for parvovirus production including an essentially serum-free medium which is suitable to increase parvovirus production compared to a standard medium, preferably for H-1PV production.

This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.